Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.

Blood Adv · 2023 · PMC10275707 · PMID 36469024

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The data showed a trend toward better tumor control with tandem and bicistronic CAR T cells cotargeting CD79a and CD19, as compared with the respective CD79b-CD19 bispecific CAR T cells ( Figure 4 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.